TAPT1_HUMAN - dbPTM
TAPT1_HUMAN - PTM Information in dbPTM
Basic Information of Protein
UniProt ID TAPT1_HUMAN
UniProt AC Q6NXT6
Protein Name Transmembrane anterior posterior transformation protein 1 homolog
Gene Name TAPT1
Organism Homo sapiens (Human).
Sequence Length 567
Subcellular Localization Cytoplasm, cytoskeleton, microtubule organizing center, centrosome . Cytoplasm, cytoskeleton, cilium basal body . Membrane
Multi-pass membrane protein .
Protein Description Plays a role in primary cilia formation. [PubMed: 26365339 May act as a downstream effector of HOXC8 possibly by transducing or transmitting extracellular information required for axial skeletal patterning during development (By similarity May be involved in cartilage and bone development (By similarity May play a role in the differentiation of cranial neural crest cells (By similarity; (Microbial infection) In case of infection, may act as a fusion receptor for cytomegalovirus (HCMV) strain AD169.]
Protein Sequence MAGVGDAAAPGEGGGGGVDGPQRDGRGEAEQPGGSGGQGPPPAPQLTETLGFYESDRRRERRRGRTELSLLRFLSAELTRGYFLEHNEAKYTERRERVYTCLRIPRELEKLMVFGIFLCLDAFLYVFTLLPLRVFLALFRLLTLPCYGLRDRRLLQPAQVCDILKGVILVICYFMMHYVDYSMMYHLIRGQSVIKLYIIYNMLEVADRLFSSFGQDILDALYWTATEPKERKRAHIGVIPHFFMAVLYVFLHAILIMVQATTLNVAFNSHNKSLLTIMMSNNFVEIKGSVFKKFEKNNLFQMSNSDIKERFTNYVLLLIVCLRNMEQFSWNPDHLWVLFPDVCMVIASEIAVDIVKHAFITKFNDITADVYSEYRASLAFDLVSSRQKNAYTDYSDSVARRMGFIPLPLAVLLIRVVTSSIKVQGILSYACVILFYFGLISLKVLNSIVLLGKSCQYVKEAKMEEKLSNPPATCTPGKPSSKSQNKCKPSQGLSTEENLSASITKQPIHQKENIIPLLVTSNSDQFLTTPDGDEKDITQDNSELKHRSSKKDLLEIDRFTICGNRID
Overview of Protein Modification Sites with Functional and Structural Information
Experimental Post-Translational Modification Sites

* ASA = Accessible Surface Area

Locations Modification Substrate Peptides
&
Secondary Structure
ASA (%) Reference Orthologous
Protein Cluster
2Acetylation------MAGVGDAAA
------CCCCCCCCC
22.7522814378
35PhosphorylationEAEQPGGSGGQGPPP
CCCCCCCCCCCCCCC
45.7422210691
47PhosphorylationPPPAPQLTETLGFYE
CCCCCCHHHHHCCCH
22.9822210691
53PhosphorylationLTETLGFYESDRRRE
HHHHHCCCHHHHHHH
16.8427642862
55PhosphorylationETLGFYESDRRRERR
HHHCCCHHHHHHHHH
25.6622210691
66PhosphorylationRERRRGRTELSLLRF
HHHHCCCHHHHHHHH
44.0723312004
75PhosphorylationLSLLRFLSAELTRGY
HHHHHHHHHHHHHCH
19.58-
90MalonylationFLEHNEAKYTERRER
HHHCCCCCCHHHHHH
46.6726320211
90UbiquitinationFLEHNEAKYTERRER
HHHCCCCCCHHHHHH
46.67-
173PhosphorylationGVILVICYFMMHYVD
HHHHHHHHHHHHHCC
5.3826552605
178PhosphorylationICYFMMHYVDYSMMY
HHHHHHHHCCHHHHH
4.1525693802
181PhosphorylationFMMHYVDYSMMYHLI
HHHHHCCHHHHHHHH
6.6025693802
182PhosphorylationMMHYVDYSMMYHLIR
HHHHCCHHHHHHHHC
7.8125693802
185PhosphorylationYVDYSMMYHLIRGQS
HCCHHHHHHHHCCCH
5.7125693802
280PhosphorylationSLLTIMMSNNFVEIK
CCEEEEECCCCEEEE
15.9629759185
303PhosphorylationKNNLFQMSNSDIKER
HCCCEECCCHHHHHH
23.5427174698
305PhosphorylationNLFQMSNSDIKERFT
CCEECCCHHHHHHHH
33.1527174698
377PhosphorylationVYSEYRASLAFDLVS
HHHHHHHHHHHHHHC
15.95-
384PhosphorylationSLAFDLVSSRQKNAY
HHHHHHHCCCCCCCC
27.4024719451
388UbiquitinationDLVSSRQKNAYTDYS
HHHCCCCCCCCCCCC
42.3021906983
441PhosphorylationLFYFGLISLKVLNSI
HHHHHHHHHHHHHHH
27.4724719451
459UbiquitinationGKSCQYVKEAKMEEK
CHHCHHHHHHHHHHH
47.20-
468PhosphorylationAKMEEKLSNPPATCT
HHHHHHHCCCCCCCC
59.3628102081
473PhosphorylationKLSNPPATCTPGKPS
HHCCCCCCCCCCCCC
23.7622199227
475PhosphorylationSNPPATCTPGKPSSK
CCCCCCCCCCCCCCC
30.6223403867
480PhosphorylationTCTPGKPSSKSQNKC
CCCCCCCCCCCCCCC
54.6127174698
481PhosphorylationCTPGKPSSKSQNKCK
CCCCCCCCCCCCCCC
44.8723403867
482UbiquitinationTPGKPSSKSQNKCKP
CCCCCCCCCCCCCCC
61.47-
483PhosphorylationPGKPSSKSQNKCKPS
CCCCCCCCCCCCCCC
40.7227174698
486UbiquitinationPSSKSQNKCKPSQGL
CCCCCCCCCCCCCCC
35.68-
500PhosphorylationLSTEENLSASITKQP
CCCHHHHCCHHHCCC
31.3926074081
502PhosphorylationTEENLSASITKQPIH
CHHHHCCHHHCCCCC
27.6725159151
504PhosphorylationENLSASITKQPIHQK
HHHCCHHHCCCCCCC
22.5626074081
511UbiquitinationTKQPIHQKENIIPLL
HCCCCCCCCCEEEEE
38.27-
520PhosphorylationNIIPLLVTSNSDQFL
CEEEEEEECCCCCCC
23.3523898821
521PhosphorylationIIPLLVTSNSDQFLT
EEEEEEECCCCCCCC
27.1923898821
523PhosphorylationPLLVTSNSDQFLTTP
EEEEECCCCCCCCCC
32.3423898821
528PhosphorylationSNSDQFLTTPDGDEK
CCCCCCCCCCCCCCC
37.2623898821
529PhosphorylationNSDQFLTTPDGDEKD
CCCCCCCCCCCCCCC
22.8721712546
538PhosphorylationDGDEKDITQDNSELK
CCCCCCCCCCCHHHC
39.7518669648
542PhosphorylationKDITQDNSELKHRSS
CCCCCCCHHHCCCCC
53.2318669648
548PhosphorylationNSELKHRSSKKDLLE
CHHHCCCCCHHHHHC
46.3530108239
549PhosphorylationSELKHRSSKKDLLEI
HHHCCCCCHHHHHCC
43.6226657352
551UbiquitinationLKHRSSKKDLLEIDR
HCCCCCHHHHHCCCC
56.40-

Upstream regulatory proteins (kinases for phosphorylation sites, E3 ubiquitin ligases of ubiquitination sites, ...)
Modified Location Modified Residue Modification Type of Upstream Proteins Gene Name of Upstream Proteins UniProt AC of Upstream Proteins Sources

Oops, there are no upstream regulatory protein records of TAPT1_HUMAN !!

Functions of PTM Sites
Modified Location Modified Residue Modification Function Reference

Oops, there are no descriptions of PTM sites of TAPT1_HUMAN !!

Disease-associated PTM Sites based on SAP

* Distance = the distance between SAP position and PTM sites.

Modified Location Modification Variant Position
(Distance <= 10)
Residue Change SAP Related Disease Reference

Oops, there are no SNP-PTM records of TAPT1_HUMAN !!

Protein-Protein Interaction
Interacting Protein Gene Name Interaction Type PPI Reference Domain-Domain Interactions

Oops, there are no PPI records of TAPT1_HUMAN !!

Drug and Disease Associations
Kegg Disease
There are no disease associations of PTM sites.
OMIM Disease
There are no disease associations of PTM sites.
Kegg Drug
There are no disease associations of PTM sites.
DrugBank
There are no disease associations of PTM sites.
Regulatory Network of TAPT1_HUMAN

loading...

Related Literatures of Post-Translational Modification
Acetylation
ReferencePubMed
"Lys-N and trypsin cover complementary parts of the phosphoproteome ina refined SCX-based approach.";
Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,Mohammed S.;
Anal. Chem. 81:4493-4501(2009).
Cited for: ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, AND MASS SPECTROMETRY.

TOP